SEC Form 4 · accession 0001209191-16-126379
Insys Therapeutics, Inc. · INSY
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Steven J Meyer
Director
Period of report
Jun 7, 2016
Accepted (ET)
Jun 7, 2016 · 9:33 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001516479
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jun 7, 2016 | M | 500 | $13.57 | A | 31,000 | D | |
| Common Stock | Jun 7, 2016 | M | 694 | $14.44 | A | 31,694 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $13.57 | Jun 7, 2016 | M | 500 | D | — | Aug 6, 2024 | Common Stock | 500 | 7,000 | D |
| Stock Option (right to buy)F2 | $14.44 | Jun 7, 2016 | M | 694 | D | — | May 1, 2026 | Common Stock | 694 | 24,306 | D |
Explanation of responses
- F1One third of the shares subject to the option vested on August 7, 2015 and the remainder vests in 24 equal monthly installments thereafter until fully vested and exercisable on August 7, 2017.
- F2The option vests in 36 equal monthly installments and will be fully vested and exercisable on May 2, 2019.